From North America: Global news and information provider Thomson Reuters (NYSE:TRI) Monday agreed to buy electronic foreign exchange platform FX Alliance (NYSE:FX), known by its trade name FXall, for about $625 million in cash.
Thomson Reuters will offer $22 per share for FXall, a premium of about 40 per cent over Friday's close of $15.70.
WellPoint (NYSE:WLP) Monday agreed to buy Amerigroup Corp. (NYSE:AGP) for $92 per share, bringing together two major managed health care companies. WellPoint valued the deal at $4.9 billion.
WellPoint's offer is at a 43 per cent premium to the company’s closing price Friday of $64.34. Amerigroup currently has about 48.5 million outstanding shares. Medicaid insurers saw their stocks soar after the deal's announcement.
Aluminum producer Alcoa (NYSE:AA) will kick off the second quarter earnings season after the bell Monday, with analysts expecting the company to report a sharp drop in profit.
The New York-based company, whose shares were down 0.52 per cent at $8.68, has been, along with other corporations, coping with a higher US dollar and a worsening European debt crisis in the second quarter.
The Boeing Co. (NYSE:BA) reported at Europe’s Farnborough Airshow on Monday that Air Lease Corp. (NYSE:AL) ordered 75 737 Max airplanes.
The order, which has a list-price of $7.2 billion, is the first 737 Max order by a leasing company, Boeing said in Monday’s statement.
Campbell Soup (NYSE:CBP) said it has entered into an agreement to acquire Bolthouse Farms from a fund managed by private equity firm Madison Dearborn Partners for $1.55 billion in cash.
Founded in 1915, Bolthouse sells beverages and dressings under the ‘Bolthouse Farms’ brand, and carrots under the ‘Bolthouse Farms’, ‘Earthbound Farms’ and ‘Green Giant’ brands.
Expectations are low for JPMorgan Chase & Co's (NYSE:JPM) second-quarter earnings which start U.S. bank reporting season Friday.
In a note from Stonecap Securities, expectations are very low for JPMorgan with EPS expected to fall 41 percent quarter-on-quarter and to be down 39 percent from prior year levels.
The Warnaco Group (NYSE:WRC) said Monday it is conducting a business review of its European-based operations to improve future growth and profitability, which is expected to result in a restructuring of the European unit.
The move stems from “challenging macroeconomic conditions” in Europe, the clothing group company said, and the recently announced transition out of its European cK bridge apparel and accessories businesses.
FTI Consulting (NYSE:FCN) said late Friday it would axe 115 jobs to realign its workforce due to global macro-economic conditions. The move will see about three per cent of its workforce terminated, and will reduce excess real estate capacity.
Bridgepoint Education (NYSE:BPI) reported Monday that it received notice last week that its Ashford University application was denied for initial accreditation by the Accrediting Commission for Senior Colleges and Universities of the Western Association of Schools and Colleges (WASC).
WASC is one of seven regional accrediting commissions that holds jurisdiction over schools located in the states of California and Hawaii, as well as the U.S. Pacific Islands. Shares of the company plunged Monday.
Canadian biotechnology company QLT Inc. (TSE:QLT)(NASDAQ:QLTI) announced Monday that it was cutting its workforce by two-thirds, leaving it with 68 employees.
The downsizing was brought on by new corporate leadership following a proxy battle waged by some of its shareholders.Among those leaving is Robert Bulchofsky, who has been QLT's president and chief executive. He has agreed to stay until July 31 as part of the transition.
SiriusXm Radio (NASDAQ:SIRI) said Monday it saw an uptick in net subscriber growth during the second quarter, triggering a revised full-year sales forecast.
The world’s largest radio broadcaster measured by sales said it added 622,042 net subscribes in second quarter, up 38 per cent from 452,147 net subscribers in 2011.
Tessera Technologies (NASDAQ:TSRA) said that it has won an interim award in a license dispute with Amkor Technology (NASDAQ:AMKR) in the International Court of Arbitration of the International Chamber of Commerce.
The company said it expects to receive at least $125 million from Amkor to resolve the amount of royalties owed under the now-terminated patent license agreement between the two parties.
Repros Therapeutics (NASDAQ:RPRX) Monday inked a deal with the Food and Drug Administration to design pivotal efficacy studies for Androxal to treat low testosterone levels.
The so called "pivotal studies" are being performed under a special protocol assessment and should start soon, the company said in a statement.
Cardiome Pharma (NASDAQ:CRME) said Monday that it is reducing its workforce by roughly 85 per cent in response to its partner Merck’s decision to terminate development efforts relating to their vernakalant oral program in March.
Vernakalant is an oral version of a heart medication that treats atrial fibrillation. An intravenous version of Cardiome's flagship product is marketed as Brinavess IV, which is approved in Europe for treating abnormal heart rhythm in adult patients.
Luminex Corp. (NASDAQ:LMNX) has agreed to acquire privately-held molecular diagnostic company GenturaDx in a $50 million cash deal.
Ampio Pharmaceuticals (NASDAQ:AMPE) announced Monday results from its Optina trial that tested adult patients with Diabetic Macular Edema (DME), an early form of diabetic retinopathy that causes significant vision loss.
Optina is an orally administered low dose of danazol used for the treatment of DME.